We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
-7.29%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$8.42B
AUM Growth
+$741M
Cap. Flow
+$3.34B
Cap. Flow %
39.69%
Top 10 Hldgs %
82.38%
Holding
65
New
2
Increased
1
Reduced
5
Closed
2

Top Sells

Rank Stock Value
1
NET icon
Cloudflare
NET
+$224M
2
OPEN icon
Opendoor
OPEN
+$59.1M
3
DM
Desktop Metal, Inc.
DM
+$43.5M
4
UPST icon
Upstart Holdings
UPST
+$35.9M
5
COUR icon
Coursera
COUR
+$27.7M

Sector Composition

Rank Sector Weight
1 Healthcare 48.15%
2 Financials 37.79%
3 Consumer Staples 5.97%
4 Industrials 3.61%
5 Technology 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EAR
26
DELISTED
Eargo, Inc. Common Stock
EAR
$30.4M 0.36%
226,034
BDTX icon
27
Black Diamond Therapeutics
BDTX
$110M
$29.2M 0.35%
3,449,845
INZY
28
DELISTED
Inozyme Pharma
INZY
$28.3M 0.34%
2,444,379
VRNA
29
DELISTED
Verona Pharma
VRNA
$27.9M 0.33%
5,108,563
AFMD
30
DELISTED
Affimed
AFMD
$27.4M 0.33%
442,649
CSPR
31
DELISTED
Casper Sleep Inc.
CSPR
$26.6M 0.32%
6,226,130
BE icon
32
Bloom Energy
BE
$67.4B
$25M 0.3%
1,333,333
AVEO
33
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$24.4M 0.29%
3,952,958
LITS
34
Lite Strategy Inc
LITS
$31.6M
$23.6M 0.28%
426,654
CTIC
35
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$21.1M 0.25%
7,140,450
PHAS
36
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$20.7M 0.25%
6,643,704
GNCA
37
DELISTED
Genocea Biosciences, Inc.
GNCA
$19.9M 0.24%
10,376,936
CBIO
38
Crescent Biopharma
CBIO
$610M
$19.9M 0.24%
90,890
GERN icon
39
Geron
GERN
$1.01B
$18.4M 0.22%
13,461,538
IVA
40
Inventiva
IVA
$1.1B
$18.4M 0.22%
1,298,700
+257,034
+25% +$3.39M
MRKR icon
41
Marker Therapeutics
MRKR
$18.7M
$18.1M 0.22%
1,071,429
ARDX icon
42
Ardelyx
ARDX
$1.2B
$18M 0.21%
13,633,582
CSBR icon
43
Champions Oncology
CSBR
$72.1M
$17.5M 0.21%
1,713,720
ELVN icon
44
Enliven Therapeutics
ELVN
$4.42B
$16.4M 0.19%
1,004,293
XENE icon
45
Xenon Pharmaceuticals
XENE
$6.24B
$15.2M 0.18%
992,107
STSA
46
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$14.6M 0.17%
3,142,958
OBSV
47
DELISTED
ObsEva SA Ordinary Shares
OBSV
$14.3M 0.17%
4,586,563
SYBX
48
DELISTED
Synlogic
SYBX
$12.9M 0.15%
281,961
LXRX icon
49
Lexicon Pharmaceuticals
LXRX
$1.05B
$11.5M 0.14%
2,382,286
MTCR
50
DELISTED
Metacrine, Inc. Common Stock
MTCR
$10.5M 0.12%
3,062,977

Similar funds

NEA Management Company's Q3 2021 Portfolio in Review

As of Q3 2021, NEA Management Company held 65 positions worth $8.42B, up 9.6% from $7.68B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

NEA Management Company deployed $3.34B of net new capital in Q3 2021, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Robinhood: 74,818,398 shares worth $3.15B.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 79% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Cloudflare, an estimated $224M trimmed.

  • NEA Management Company's largest Q3 2021 buy was Robinhood: 74,818,398 shares worth $3.15B.
  • NEA Management Company added most to Inventiva in Q3 2021, an estimated $3.39M increase.
  • NEA Management Company's biggest Q3 2021 reduction was Cloudflare, cutting an estimated $224M.
  • NEA Management Company fully exited Opendoor in Q3 2021, selling an estimated $59.1M.
  • NEA Management Company's ten largest holdings make up 82% of its $8.42B portfolio in Q3 2021.
  • NEA Management Company opened 2 new positions and closed 2 in Q3 2021.
  • NEA Management Company's portfolio value rose 9.6% quarter-over-quarter to $8.42B.

Based on NEA Management Company's 13F filing for Q3 2021, filed 12 Nov 2021.